Every 8-K that Clearside Biomedical, Inc. (CLSD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLSD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLSD filings page.
Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy and faces delisting from Nasdaq. On November 23, 2025, the company voluntarily filed for relief under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and will continue operating as a debtor-in-possession while seeking Court approval for various first-day motions to keep its business running. The company’s stated objective in the case is to sell substantially all of its assets to the highest bidder.
On November 24, 2025, Nasdaq notified Clearside that, due to the bankruptcy case and prior noncompliance with the minimum Market Value of Listed Securities requirement of $50,000,000, its common stock will be delisted. Trading on Nasdaq is expected to be suspended at the opening of business on December 1, 2025, after which the shares are expected to trade on the OTC market under the symbol CLSDQ.
Clearside Biomedical, Inc. disclosed that Nasdaq notified the company it was non-compliant with the exchange's minimum bid price rule because the company's common stock traded below $1.00 per share for the prior 30 consecutive business days. The company failed to regain compliance within the standard 180‑calendar day cure period ending on August 6, 2025, and Nasdaq advised on August 11, 2025 that the securities are subject to delisting unless a timely hearing is requested.
Clearside Biomedical, Inc. (CLSD) amended its charter to implement a one-for-fifteen reverse stock split of its common stock and to reduce authorized common shares from 400,000,000 to 26,666,666. The amendment will become effective at 5:00 p.m. Eastern Time on September 12, 2025. Stockholders approved a series of alternate amendments at a Special Meeting on August 29, 2025, and the board selected the specific 1-for-15 split and corresponding authorized share reduction on September 4, 2025. The filing reports these charter changes only; no additional operational, financial, or forward-looking information is provided.
Clearside Biomedical announced a one-for-fifteen reverse stock split and a reduction in authorized common shares. The company will effect a 1-for-15 reverse split of its outstanding common stock and reduce authorized common shares from 400,000,000 to 26,666,666. The certificate amendment implementing these changes becomes effective at 5:00 p.m. Eastern Time on September 12, 2025. Stockholders approved a series of alternate amendments, including the reverse split and authorized-share reduction, at a Special Meeting on August 29, 2025, and the board adopted the specific 1-for-15 split and corresponding reduction on September 4, 2025.
Clearside Biomedical, Inc. disclosed a material transaction in which the seller in a purchase arrangement received $32.5 million. To secure obligations under the Purchase Agreement, the company granted a Pledge Agreement that pledged the seller's capital stock as collateral. The agreement gives the Purchaser Agent the right to foreclose on that pledged stock if certain events occur, creating a potential claim on ownership of the Seller's equity. The filing describes the financing and collateral arrangement but does not provide further financial detail or timing for any enforcement.
Clearside Biomedical, Inc. reported that on August 28, 2025 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Global Market’s minimum Market Value of Listed Securities requirement of $50,000,000. The notice does not immediately affect trading, and the company has until February 24, 2026 to regain compliance by maintaining an MVLS of at least $50,000,000 for 10 consecutive business days.
The company is already in the hearings process after a prior Nasdaq staff determination to delist its shares for failing to meet the $1.00 minimum bid price rule. To address this, stockholders approved a proposal at a special meeting on August 29, 2025 authorizing the board to implement a reverse stock split in a range of 1‑for‑5 to 1‑for‑15 and to proportionally reduce authorized common shares. The proposal passed with 46,485,055 votes for, 2,220,186 against, and 458,996 abstentions out of 49,164,237 shares represented.